PDS Biotechnology Ends Q4 With $26.7M Cash, Amends VERSATILE-003 Trial Timeline
PDS Biotechnology ended Q4 2025 with $26.7 million in cash and reduced net loss and operating expenses year-over-year. It amended the VERSATILE-003 trial to target final results in one year, with an interim PFS analysis at 1.5 years; filed new US and Japan patents extending IP protection into the 2040s.
1. Financial Discipline and Cash Position
PDS Biotechnology reported a cash balance of $26.7 million as of December 31, 2025, and achieved year-over-year reductions in net loss and operating expenses. The company has not provided specific financial guidance for 2026, creating uncertainty around future R&D spending and overall financial flexibility.
2. Amended VERSATILE-003 Trial Design
The Phase III VERSATILE-003 trial protocol was revised to shorten the expected duration to approximately one year for final results, with an interim progression-free survival analysis planned at 1.5 years. This amendment supports a smaller sample size, potential accelerated review, robust enrollment pace, and retention of all existing trial sites.
3. Strengthened Patent Portfolio
PDS Biotechnology secured new patents in both the United States and Japan, extending intellectual property protection for its core immunotherapy technology into the 2040s. This expansion bolsters the company’s long-term market exclusivity and competitive positioning.